A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants

by palligoelme@gmail.com | Feb 17, 2026 | Clinical Trials

​ Conditions: Pharmakokinetic; Open Label; Phase 1 Interventions: Drug: TNX-102 SL Tablet Sponsors: Tonix Pharmaceuticals, Inc.; Syneos Health Active, not recruiting Conditions: Pharmakokinetic; Open Label; Phase 1 Interventions: Drug: TNX-102 SL Tablet Sponsors:...

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

by palligoelme@gmail.com | Feb 17, 2026 | Clinical Trials

​ Conditions: Healthy Volunteer Interventions: Drug: ABBV-8736; Drug: ABBV-8736 Sponsors: AbbVie Not yet recruiting Conditions: Healthy Volunteer Interventions: Drug: ABBV-8736; Drug: ABBV-8736 Sponsors: AbbVie Not yet...

Repeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration

by palligoelme@gmail.com | Feb 13, 2026 | Clinical Trials

​ Conditions: AMD – Age-Related Macular Degeneration Interventions: Device: RLRL device; Device: Sham device Sponsors: The Hong Kong Polytechnic University Not yet recruiting Conditions: AMD – Age-Related Macular Degeneration Interventions: Device: RLRL...

Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy

by palligoelme@gmail.com | Feb 13, 2026 | Clinical Trials

​ Conditions: Hypertrophic Cardiomyopathy (HCM) Interventions: Other: Observational study, no new intervention offered Sponsors: University of Manchester Not yet recruiting Conditions: Hypertrophic Cardiomyopathy (HCM) Interventions: Other: Observational study, no new...

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

by palligoelme@gmail.com | Feb 13, 2026 | Clinical Trials

​ Conditions: Breast Cancer Interventions: Drug: Imlunestrant + abemaciclib; Drug: (dd)EC*4-T*4 Sponsors: Fudan University Not yet recruiting Conditions: Breast Cancer Interventions: Drug: Imlunestrant + abemaciclib; Drug: (dd)EC*4-T*4 Sponsors: Fudan University Not...